Enochian Biosciences (NASDAQ:LNAI) Downgraded to “Strong Sell” Rating by Wall Street Zen

Wall Street Zen downgraded shares of Enochian Biosciences (NASDAQ:LNAI) to a strong sell rating in a report released on Friday.

Enochian Biosciences Price Performance

NASDAQ:LNAI opened at $1.29 on Friday. The firm has a market capitalization of $22.20 million, a price-to-earnings ratio of -0.17 and a beta of 0.39. Enochian Biosciences has a 1 year low of $1.13 and a 1 year high of $21.00.

Enochian Biosciences (NASDAQ:LNAI) last released its quarterly earnings data on Monday, September 29th. The company reported ($7.60) earnings per share (EPS) for the quarter.

About Enochian Biosciences

Enochian Biosciences, Inc, a pre-clinical stage biotechnology company, engages in the research and development of pharmaceutical and biological products for the human treatment of human immunodeficiency virus (HIV), hepatitis B virus (HBV), influenza and coronavirus infections, and cancer. The company’s lead candidate includes ENOB-HV-01 for autologous HIV curative treatment; ENOB-HV-11, a preventative HIV vaccine; ENOB-HV-12, a therapeutic HIV vaccine; and ENOB-HB-01, a coopting HBV polymerase.